Oncology and Targeted Cancer Therapies
Bluepharma Industria Farmaceutica S.A. supports clinical research centered on oral therapies used in oncology, with activity spanning thyroid carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
- Lenvatinib
- Cabozantinib
- Nilotinib
Its research portfolio also includes agents relevant to chronic myelogenous leukemia and other malignancies requiring targeted systemic treatment.
Hematology and Blood Disorders
The sponsor funds studies in hematologic disease areas involving both malignant and non-malignant conditions, with attention to therapies used in thrombocytopenia and aplastic anemia.
- Eltrombopag
- Ruxolitinib
- Tofacitinib
Research in this area includes medicines associated with platelet support and treatment of disorders affecting bone marrow and blood cell production.
Thyroid and Endocrine Oncology
Clinical activity also covers treatment options for differentiated thyroid carcinoma, particularly disease that is radioactive iodine-refractory and progressive or metastatic.
- Lenvatinib
- Cabozantinib
This area reflects interest in oral anticancer medicines used in advanced endocrine malignancies.
Comparative Bioavailability and Bioequivalence
Much of the sponsor’s research landscape is focused on bioequivalence and comparative bioavailability studies for film-coated tablets and hard capsules in healthy participants.
- Fasting conditions
- Fed conditions
- Reference products
These studies support evaluation of oral formulations across different administration conditions for medicines used in oncology and hematology.
